Table 1.

Patient characteristics.

Pt	Age	Sex	Diagnosis	Treatment	Local side effects	Systemic side effects	Pre anti-N IgG OD	Pre anti-S IgG EC50	Post anti-S IgG EC50	Post neut. Ab ID50	Post CD4+	Post CD8+
01	55	F	ET	Peg-IFN	None	None	0.317	<25	25	95	+	+
02	62	M	ET	Peg-IFN	None	Fatigue	0.204	<25	31	243	+	+
03	47	M	MF	Surveillance	Localised inflammation	None	0.228	<25	<25	133	NA	NA
04	50	F	PV	Surveillance/ Venesection	None	None	0.243	<25	<25	<25	+	+
05	63	F	ET	Surveillance	Localised inflammation	None	0.207	<25	25	156	−	−
06	37	M	PV	HC	None	Headache, Fatigue	0.339	<25	810	2163	+	−
07	43	F	MF	Ruxolitinib	None	Dizziness	0.256	<25	<25	<25	+	−
08	63	F	MF	Ruxolitinib	Localised inflammation	Fatigue	0.900	25	5788	3999	+	−
09	40	F	ET	Surveillance	None	Diarrhoea	0.326	<25	457	689	−	−
10	72	M	MF	Surveillance	Localised inflammation	None	1.772	41	9618	13709	+	+
11	64	F	MF	Surveillance	Localised inflammation	None	0.266	25	8783	15417	+	+
12	64	F	ET	HC	Localised inflammation	Fatigue	0.194	<25	25	127	−	−
13	36	M	MF	Ruxolitinib IMG-7289	None	None	0.187	<25	25	381	+	+
14	59	F	MF	Ruxolitinib	None	None	0.216	<25	<25	<25	+	−
15	70	F	PV	Ruxolitinib	Localised inflammation	Fatigue	0.194	<25	25	98	−	−
16	59	M	ET	Peg-IFN	Localised inflammation	Flu-like illness	0.242	<25	358	1151	+	−
17	58	M	MF	Ruxolitinib	None	Flu-like illness	1.504	25	6460	23823	+	−
18	58	F	ET	HC	Localised inflammation	Nausea	0.198	<25	120	533	+	−
19	40	F	ET	Peg-IFN	Localised inflammation	None	0.370	<25	25	366	+	+
20	60	F	MF	Hydroxy-carbamide	Localised inflammation	None	1.739	<25	457	1977	+	−
21	56	F	PV	Surveillance/Venesection	Localised inflammation	None	0.099	NA	< 25	213	−	−

EC50 50% effective concentration, ET essential thrombocythaemia, HC hydroxycarbamide, ID50 50% inhibitory dilution, MF myelofibrosis, Peg-IFN pegylated interferon, PV polycythaemia vera.